⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17342284 | 1.00 | — | — | |
| SCHEMBL7837579 | 0.83 | BRD4 (0.39) | — | |
| SCHEMBL25280759 | 0.81 | CRBN (0.40) | — | |
| SCHEMBL16109535 | 0.80 | — | — | |
| SCHEMBL26064924 | 0.80 | — | — | |
| SCHEMBL19883127 | 0.78 | — | — | |
| SCHEMBL5451213 | 0.78 | — | — | |
| SCHEMBL13575606 | 0.78 | — | — | |
| SCHEMBL8299815 | 0.78 | — | — | |
| SCHEMBL319650 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-02-02 | — | — | US | claimed |
| US-9499522-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-11-22 | — | — | US | claimed |
| EP-2970231-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | Blueprint Medicines Corporation (US) | 2016-01-20 | — | — | EP | claimed |
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | US | claimed |
| WO-2014160521-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | WO | claimed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025076088-A1 | LACTAMS FOR USE AS SARM1 INHIBITORS | GENENTECH, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240360152-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008016973-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2008-02-07 | — | — | WO | disclosed |
| US-5965578-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0897303-A4 | — | — | 1999-02-24 | — | — | EP | disclosed |
| EP-0897303-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1997036605-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |